Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.
B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell-targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell-targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell-targeted approach predicated on the induction of B cell anergy.
Department of Immunology, University of Colorado and National Jewish Health, Denver, CO 80206;
Ian R
IR
Hardy
Nadia
N
Anceriz
François
F
Rousseau
Matt B
MB
Seefeldt
Eric
E
Hatterer
Magali
M
Irla
Vanessa
V
Buatois
Laurence E
LE
Chatel
Andrew
A
Getahun
Ashley
A
Fletcher
Laura
L
Cons
Guillemette
G
Pontini
Nicole A
NA
Hertzberg
Giovanni
G
Magistrelli
Pauline
P
Malinge
Mia J
MJ
Smith
Walter
W
Reith
Marie H
MH
Kosco-Vilbois
Walter G
WG
Ferlin
John C
JC
Cambier
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001327:Autoimmune Diseases / Q000517:prevention & control*; D015551:Autoimmunity / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D051925:CD79 Antigens / Q000276:immunology*; D017635:Clonal Anergy / Q000276:immunology*; D005260:Female; D008213:Lymphocyte Activation / Q000276:immunology; D018655:Lymphocyte Count; D008212:Lymphocyte Depletion; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D018345:Mice, Knockout
D000911:Antibodies, Monoclonal; D051925:CD79 Antigens